SYRS (Syros Pharmaceuticals) E10: $-39.08 (As of Sep. 2024)


SYRS Syros Pharmaceuticals Inc SYRS
12 GF Score
Price $0.00
View Full Analysis

What is Syros Pharmaceuticals E10?

Syros Pharmaceuticals SYRS 12 E10 is $-39.08 as of Sep. 2024. GuruFocus rates SYRS with a GF Score™ of 12/100.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

Syros Pharmaceuticals's adjusted earnings per share data for the three months ended in Sep. 2024 was $-0.160. Add all the adjusted EPS for the past 10 years together and divide 10 will get our e10, which is $-39.08 for the trailing ten years ended in Sep. 2024.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the E10 growth rate using E10 data.

As of today (2026-06-26), Syros Pharmaceuticals's current stock price is $0.0001. Syros Pharmaceuticals's E10 for the quarter that ended in Sep. 2024 was $-39.08. Syros Pharmaceuticals's Shiller PE Ratio of today is .


Syros Pharmaceuticals  (OTCPK:SYRS) E10 Explanation

If a company grows much fast than inflation, E10 may underestimate the company's earnings power. Shiller PE Ratio can seem to be too high even the actual P/E is low.

For the Shiller P/E, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller P/E is also called PE10.

The Shiller P/E was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.


Be Aware

Shiller PE Ratio works better for cyclical companies. It gives you a better idea on the company's real earnings power.


Syros Pharmaceuticals E10 Related Terms


Syros Pharmaceuticals E10 Historical Data

* Premium members only.

The historical data trend for Syros Pharmaceuticals's E10 can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Syros Pharmaceuticals E10 Chart

Syros Pharmaceuticals Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
E10
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Syros Pharmaceuticals Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
E10 Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 -39.08

SYRS vs AFMDQ, BTAX, TRVN: E10 Comparison

For the Biotechnology subindustry, Syros Pharmaceuticals's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Syros Pharmaceuticals Shiller PE Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Syros Pharmaceuticals's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Syros Pharmaceuticals's Shiller PE Ratio falls into.


SYRS
12GF Score
Syros Pharmaceuticals Inc SYRS
E10 is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Syros Pharmaceuticals E10 Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. When we calculate the today's Shiller P/E ratio of a stock, we use today's price divided by E10.

What is E10? How do we calculate E10?

E10 is the average of the inflation adjusted earnings of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the E10 of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the earnings from 2001 through 2010.

We adjusted the earnings of 2001 earnings data with the total inflation from 2001 through 2010 to the equivalent earnings in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart earned $1 a share in 2001, then the 2001's equivalent earnings in 2010 is $1.4 a share. If Wal-Mart earns $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 earnings in 2010 is $1.35. So on and so forth, you get the equivalent earnings of past 10 years. Then you add them together and divided the sum by 10 to get E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Syros Pharmaceuticals's adjusted earnings per share data for the three months ended in Sep. 2024 was:

Adj_EPS= Earnings per Share (Diluted) /CPI of Sep. 2024 (Change)*Current CPI (Sep. 2024)
=-0.16/315.3010*315.3010
=-0.160

Current CPI (Sep. 2024) = 315.3010.

Syros Pharmaceuticals Quarterly Data

per share eps CPI Adj_EPS
201412 0.000 234.812 0.000
201503 -3.223 236.119 -4.304
201506 -28.698 238.638 -37.917
201509 -38.020 237.945 -50.380
201512 -46.739 236.525 -62.306
201603 -5.415 238.132 -7.170
201606 -54.200 241.018 -70.905
201609 -6.500 241.428 -8.489
201612 -4.690 241.432 -6.125
201703 -4.900 243.801 -6.337
201706 -5.200 244.955 -6.693
201709 -5.300 246.819 -6.771
201712 -5.800 246.524 -7.418
201803 -4.800 249.554 -6.065
201806 -4.300 251.989 -5.380
201809 -4.700 252.439 -5.870
201812 -5.400 251.233 -6.777
201903 -4.900 254.202 -6.078
201906 -4.700 256.143 -5.785
201909 -4.700 256.759 -5.772
201912 -4.600 256.974 -5.644
202003 -3.900 258.115 -4.764
202006 -3.800 257.797 -4.648
202009 -4.300 260.280 -5.209
202012 -6.300 260.474 -7.626
202103 -2.300 264.877 -2.738
202106 -3.600 271.696 -4.178
202109 -4.140 274.310 -4.759
202112 -3.780 278.802 -4.275
202203 -3.990 287.504 -4.376
202206 -5.400 296.311 -5.746
202209 -3.210 296.808 -3.410
202212 -0.236 296.797 -0.251
202303 -0.850 301.836 -0.888
202306 -1.300 305.109 -1.343
202309 -1.430 307.789 -1.465
202312 -2.220 306.746 -2.282
202403 -0.100 312.332 -0.101
202406 -0.590 314.175 -0.592
202409 -0.160 315.301 -0.160

Add all the adjusted EPS together and divide 10 will get our e10.

Frequently Asked Questions Learn more about E10 →
What does a E10 of $-39.08 mean?
Syros Pharmaceuticals (SYRS) has a E10 of $-39.08 as of Sep. 2024. E10 represents the company's inflation-adjusted earnings per share over a 10-year period. View historical data on Syros Pharmaceuticals and its competitors.
Is Syros Pharmaceuticals' E10 too high?
Syros Pharmaceuticals' current E10 is $-39.08. Overall, Syros Pharmaceuticals has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Syros Pharmaceuticals' E10 compare to AFMDQ and BTAX?
Syros Pharmaceuticals' E10 of $-39.08 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good E10 for a Biotechnology company?
A good E10 depends on the Biotechnology industry context. However, E10 should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high E10 mean?
A high E10 can signal that a stock is expensive relative to its fundamentals. E10 represents the company's inflation-adjusted earnings per share over a 10-year period. View historical data on Syros Pharmaceuticals and its competitors. Syros Pharmaceuticals's current E10 is $-39.08. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Syros Pharmaceuticals stock overvalued right now?
Syros Pharmaceuticals (SYRS) has a current E10 of $-39.08. The current E10 is $-39.08. Syros Pharmaceuticals' overall GF Score™ is 12/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is E10 calculated?
E10 is calculated from a company's financial statements. For Syros Pharmaceuticals (SYRS), the current E10 is $-39.08 as of Sep. 2024. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Syros Pharmaceuticals Business Description

Address 35 CambridgePark Drive, 4th Floor, Cambridge, MA, USA, 02140
Syros Pharmaceuticals Inc is a biopharmaceutical company committed to developing new standards of care for the frontline treatment of patients with hematologic malignancies.
12GF Score

Get the complete analysis for SYRS

E10 is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.00
Price